636 Addition of GITR agonist to a dark matter cancer vaccine and anti-PD-1 increases regulatory T cell numbers without appearing to impact therapeutic efficacy
Rom S. Leidner(Providence Portland Medical Center), Bernard A. Fox(Oregon Health & Science University), Christopher Paustian(UbiVac (United States)), Elizabeth Gould(The University of Texas at San Antonio Health Science Center), Lakhvir Kaur(Providence Portland Medical Center), Tarsem L Moudgil(Providence Portland Medical Center), Marcus Couey(Providence Portland Medical Center), Ryan Meng(Providence Portland Medical Center), Walter J. Urba(Providence Portland Medical Center), Matthew H. Taylor(Providence Portland Medical Center), Shawn M. Jensen(Providence Portland Medical Center), Tanisha Christie(Providence Portland Medical Center), Venkatesh Rajamanickam(Cancer Institute (WIA)), Carlo Bifulco(Providence Health & Services), Noah D. Simons(Providence Portland Medical Center), Brady Bernard(Providence Portland Medical Center), Traci Hilton(UbiVac (United States)), Yoshinobu Koguchi(Providence Portland Medical Center), Brian Piening(Providence College), Bryan Bell(Providence Portland Medical Center), Robert Michael Hermann(Providence Portland Medical Center), Hong‐Ming Hu(Viva Biotech (China)), Patrick Rethwisch(Providence Portland Medical Center), William L. Redmond(Providence St. Vincent Medical Center)
Cited by 0
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k